Arcutis Biotherapeutics (ARQT) vs Bausch Health Companies (BHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bausch Health Companies (BHC) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 36.3% versus a loss of 10.6%. Over five years, ARQT leads with a +58.1% price change compared with -67.4% for BHC. Arcutis Biotherapeutics is the larger company by market cap ($3.33 billion vs $3.08 billion), about 1.1 times the size.
On valuation, Bausch Health Companies trades at a lower forward P/E (1.9x vs 24.1x for Arcutis Biotherapeutics). Bausch Health Companies converts more of its revenue into profit, with a net margin of 1.5% versus -4.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | BHC |
|---|---|---|
| Share price | $26.36 | $8.22 |
| Market cap | $3.33B | $3.08B |
| 1-day change | -2.98% | -3.97% |
| YTD return | -9.23% | +18.27% |
| 1-year return | -10.61% | +36.32% |
| 5-year return | +58.13% | -67.45% |
| P/E ratio (TTM) | 119.82 | — |
| Forward P/E | 24.09 | 1.89 |
| EPS (TTM) | $0.22 | $-2.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | $10.27B |
| Revenue growth (YoY) | +91.34% | +6.66% |
| Net income (latest FY) | $-16.14M | $157.00M |
| Gross margin | 90.24% | — |
| Operating margin | -3.25% | 17.66% |
| Net margin | -4.29% | 1.53% |
| 52-week high | $34.80 | $9.04 |
| 52-week low | $19.30 | $4.33 |
| Distance from 52-week high | -24.25% | -9.07% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +53.19% | +2.19% |
| Average volume | 2.58M | 3.16M |
| Shares outstanding | 126.46M | 374.27M |
| Employees | 354 | 20,300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BHC has outperformed ARQT by 46.9 percentage points over the past year.
- Bausch Health Companies is more profitable, keeping 1.5 cents of every revenue dollar as net income versus -4.3 cents for Arcutis Biotherapeutics.
- Arcutis Biotherapeutics grew revenue faster in its latest fiscal year (+91.34% vs +6.66%).
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
ARQT vs BHC FAQ
Which is bigger, Arcutis Biotherapeutics or Bausch Health Companies?
Arcutis Biotherapeutics (ARQT) is larger, with a market capitalization of $3.33B compared with $3.08B for Bausch Health Companies (BHC).
Which stock has performed better over the past year, ARQT or BHC?
BHC returned +36.32% over the past 12 months, compared with -10.61% for ARQT (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and Bausch Health Companies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.